Medtronic's Pioneering Clinical Trial Results for Hugo™ RAS
The Expand URO Investigational Device Exemption (IDE) clinical trial has emerged as a significant milestone for the Hugo™ robotic-assisted surgery (RAS) system. As the largest multi-center IDE study conducted in urology, it showcases promising results regarding safety and efficacy in robotic-assisted surgeries.
Landmark Study Results
Medtronic (NYSE: MDT), recognized as a leading innovator in healthcare technology, has announced that the Expand URO study successfully met both primary safety and effectiveness endpoints. This prospective, multi-center trial involved 137 patients who underwent various urologic procedures utilizing the Hugo RAS system.
Study Presentation at AUA Annual Meeting
The findings of the study were presented by Dr. Michael R. Abern, a leading urologic surgeon, at the annual meeting of the American Urologic Association (AUA). Dr. Abern emphasized that the trial's results confirmed the Hugo RAS system’s alignment with current literature on robotic-assisted urologic surgeries.
Dr. Abern stated, "The study demonstrated that the Hugo RAS system met the safety and effectiveness endpoints, and the outcomes are consistent with published literature for robotic-assisted urologic surgery. It's rewarding to see the results of this rigorous study in robotic surgery."
Details of the Expand URO Clinical Study
This pivotal trial comprised patients averaging around 63 years of age, classified as American Society of Anesthesiologists (ASA) category ?3. This signifies a cohort with significant underlying health conditions. Notably, the study was conducted by a team of 11 surgeons across six hospitals.
Types of Procedures Analyzed
The study included three primary types of urologic procedures: prostatectomies (55 cases), nephrectomies (53 cases), and cystectomies (29 cases). The patient cohorts involved were diagnosed mainly with prostate cancer, renal tumors, and bladder tumors.
The rigorous clinical protocols adhered to the FDA premarket requirements, ensuring a comprehensive approach with prospective enrollment, independent event adjudication, and high patient follow-up compliance.
Results of Primary Endpoints
The study reported several noteworthy findings:
- The overall safety rates showed that only 3.7% of prostatectomies, 1.9% of nephrectomies, and 17.9% of cystectomies resulted in grade 3 or higher complications, all well below the predetermined performance goals.
- On effectiveness, the Hugo RAS system showcased an impressive surgical success rate of 98.5%, significantly surpassing the established performance goal of 85%.
Next Steps for Medtronic
Medtronic has also confirmed that it has submitted the Hugo RAS system to the U.S. Food and Drug Administration (FDA) following the developments in this clinical study. This submission is a strategic step as the company aims to make its mark in the U.S., which is the largest market for robotic surgery technologies.
Moreover, Medtronic has carried out multiple other studies within the same timeframe, encompassing hernia and benign gynecology procedures and has garnered FDA approval for additional clinical research.
Globally, the Hugo RAS system is already in clinical use across over 25 countries, backed by a robust body of evidence, with more than 200 independent papers published to date.
Design and Functionality of the Hugo RAS System
The Hugo RAS system has been meticulously developed through collaboration with hundreds of global surgeons and healthcare leaders. Its design facilitates increased accessibility to minimally invasive surgical care, boasting a modular framework and open surgeon console for improved communication during operations.
Furthermore, the Hugo system works in synergy with the Touch Surgery™ ecosystem, creating a connected surgical environment aimed at optimizing surgical experiences.
About Medtronic
Medtronic plc, headquartered in Galway, Ireland, is committed to combating the world's most pressing health challenges through innovative healthcare solutions. With over 95,000 team members dedicated to improving lives, the company's mission centers on alleviating pain, restoring health, and extending life. Medtronic delivers a spectrum of technologies addressing numerous health conditions, catering to the needs of patients and healthcare professionals alike.
Frequently Asked Questions
What is the Hugo RAS system?
The Hugo RAS system is a modular robotic-assisted surgery platform designed to facilitate various urologic procedures with a focus on minimally invasive techniques.
What were the primary findings of the Expand URO study?
The study met crucial safety and effectiveness endpoints, showing a low complication rate and a surgical success rate significantly exceeding expectations.
Who presented the study results?
The results were presented by Dr. Michael R. Abern, a renowned urologic surgeon during the AUA annual meeting.
How does the Hugo RAS system enhance surgical procedures?
It allows for enhanced communication among surgical teams, promotes minimally invasive techniques, and supports a connected surgical experience.
Where is the Hugo RAS system currently used?
It is in clinical use across more than 25 countries worldwide, continuously supported by extensive research and published studies.
